PROXIMAGEN
Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.
PROXIMAGEN
Industry:
Biotechnology Health Care Medical Medical Device
Founded:
2003-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.proximagen.com
Total Employee:
11+
Status:
Closed
Contact:
44 20 7400 7700
Email Addresses:
[email protected]
Total Funding:
96.5 M USD
Technology used in webpage:
Microsoft Exchange Online Microsoft Azure DNS Pound Sterling Digital Ocean Namesco DNS
Similar Organizations
Avacta Animal Health
Avacta Animal Health is an veterinary laboratory service provider and diagnostic tester to surgeons, laboratories on animal allergies.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-01-05 | Minster Pharmaceuticals | Minster Pharmaceuticals acquired by Proximagen | 4.3 M GBP |
| 2009-10-30 | Cambridge Biotechnology | Cambridge Biotechnology acquired by Proximagen | N/A |
Investors List
Lundbeck
Lundbeck investment in Venture Round - Proximagen
Official Site Inspections
http://www.proximagen.com
- Host name: 159.203.250.219
- IP address: 159.203.250.219
- Location: San Francisco United States
- Latitude: 37.7353
- Longitude: -122.3732
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94124
More informations about "Proximagen" on Search Engine
Proximagen (now BenevolentAI) | LinkedIn
Cambridge, Cambridge 1,921 followers. View all 3 employees. About us. In February 2018, Proximagen Limited was acquired by BenevolentAI. Benevolent AI is one of the largest …See details»
Inside BenevolentAI: the $2bn tech company backed by …
Jun 18, 2019 Founded by Ken Mulvany in late 2013, BenevolentAI aims to use its technology to comb vast troves of medical data — from clinical …See details»
Proximagen - Crunchbase Company Profile & Funding
Phone Number 44 20 7400 7700. Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including …See details»
Proximagen Company Profile - Craft
Proximagen is a company engaged in small molecule drug discovery and focused on research and development of central nervous system disorders. The Company develops …See details»
Proximagen Acquires Two CNS Drug Development Programmes …
Dec 21, 2010 Proximagen Group plc, the rapidly growing company with a principal focus on the treatment of disorders of the central nervous system (“CNS”), today announces …See details»
Upsher-Smith to acquire biotechnology firm Proximagen Group
MAPLE GROVE, Minn. — Upsher-Smith Labs on Wednesday announced that it has agreed to acquire Proximagen Group, a European biotechnology company focused on the …See details»
MRC Technology and Proximagen Collaborate
Oct 13, 2014 MRC Technology and Proximagen Group Limited have entered into collaboration to progress small molecules for the treatment of inflammatory and …See details»
Proximagen - Funding, Financials, Valuation & Investors
Proximagen is a neuroscience research company developing drugs for neurodegenerative disorders, including Parkinson’s and Alzheimers.See details»
Roche And Upsher-Smith Announce License Agreement To …
Dec 1, 2015 Since 2012, Proximagen has been a wholly-owned subsidiary of Upsher-Smith. With an integrated drug discovery facility based in Cambridge, UK, Proximagen …See details»
Proximagen acquires Minster Pharmaceuticals - 2010-01-05
Jan 5, 2010 Acquiring Organization: Proximagen Proximagen is a neuroscience research company developing drugs for neurodegenerative disorders, including Parkinson’s and …See details»
UCB to expand epilepsy portfolio with strategic acquisition of ...
Apr 20, 2018 Proximagen LLC, a member of the ACOVA family of companies located in Plymouth MN (USA), specializes in the development of novel small molecule …See details»
Research programme: small molecule therapeutics - Proximagen
If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely. IP authentication when working within …See details»
Upsher-Smith Completes Acquisition of Proximagen Group plc
Aug 14, 2012 today announced that on Tuesday, August 14, 2012 it completed its acquisition of UK-based Proximagen Group plc (AIM: PRX), a European biotechnology …See details»
Research programme: small molecule therapeutics
If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely. IP authentication when working within …See details»
Proximagen Neuroscience | VentureRadar
Proximagen is based on the expertise of Professor Peter Jenner, one of the world's leading authorities on neuro-degenerative diseases. It provides... ... Find out more about …See details»
Proximagen - Tech Stack, Apps, Patents & Trademarks
Proximagen is a neuroscience research company developing drugs for neurodegenerative disorders, including Parkinson’s and Alzheimers.See details»
Proxima CRO
Dec 6, 2017 About Proxima. Our team of Clinical, Regulatory, and Quality experts have led Proxima to the forefront of the healthcare industry. We continuously meet milestones, …See details»
Proximagen - Contacts, Employees, Board Members, Advisors
Proximagen is a neuroscience research company developing drugs for neurodegenerative disorders, including Parkinson’s and Alzheimers.See details»
Research programme: Parkinson's disease therapeutics
Research programme: Parkinson's disease therapeutics - Proximagen/Upsher-Smith Alternative Names: PRX-1; PRX-1235; PRX-2; PRX-5 Latest Information Update: 04 Nov …See details»
Research programme: Alzheimer's disease therapeutics
Proximagen Neuroscience in the United Kingdom was engaged in the discovery of a series of proprietary compounds in its PRX 4006 programme as potential.See details»